跳至主要内容
临床试验/NCT01729351
NCT01729351已完成不适用

Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone and Chlorofluorocarbon Beclometasone in Smoking Asthma - a Retrospective, Real-life Observational Study in a UK Primary Care Asthma Population

Research in Real-Life Ltd0 个研究点目标入组 7,195 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
7,195
主要终点
Asthma Control proxy incorporating SABA use

研究概览

简要总结

To evaluate the comparative effectiveness of extrafine hydrofluoroalkane beclometasone (EF HFA-BDP) and other inhaled corticosteroid (ICS) therapy commonly used in the UK, specifically fluticasone (FP) and non-extrafine (NEF) BDP (CFC-BDP and NEF HFA-BDP) in a UK primary care asthma population of current smokers.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
16 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 16-70 years
  • Current smokers - explicitly coded in patient records or captured in patient questionnaires
  • Evidence of asthma diagnosis and current therapy: ≥2 prescriptions for asthma at different points in time during the baseline year ± a diagnostic code for asthma
  • On-going asthma therapy: ≥2 prescription for ICS during the outcome period (i.e. ≥1 prescription in addition to IPD prescription)
  • ≥2 years continuous data (i.e. ≥1 year of baseline plus ≥1 year of outcome data)

排除标准

  • Patients will be excluded from the analysis if they have:
  • Any chronic respiratory disease other than asthma
  • Are prescribed:
  • Maintenance oral steroid therapy during the baseline year
  • Combination ICS/long-acting beta agonist (LABA) therapy during baseline year or at IPD
  • Multiple ICS prescriptions at IPD or immediately before .

结局指标

主要结局

Asthma Control proxy incorporating SABA use

时间窗: 1 year

Where control is defined as absence of: (i)Respiratory-related: Hospital attendance or admission A\&E attendance, OR Out of hours attendance, OR Out-patient department attendance (ii)GP consultations for lower respiratory tract infection (iii)Prescriptions for acute courses of oral steroids (iv)Average prescribed daily dose of albuterol or terbutaline of ≤200mg

Asthma Exacerbations (ATS Definition)

时间窗: 1 year

Defined as an absence of the the following: 1. Asthma related hospital attendance or admission, OR A\&E attendance, OR 2. Use of acute oral steroids.

次要结局

  • Exacerbation definition based on clinical experience(1 year)
  • Asthma control proxy excluding SABA usage(1 year)
  • Treatment Success(1 year)
  • Definite asthma-related hospitalisations(1 year)
  • ICS Compliance(1 year)
  • Incidence of oral thrust(1 year)
  • SABA Dose(1 year)
  • Definite and probable asthma-related hospitalisations(1 year)

研究者

发起方
Research in Real-Life Ltd
申办方类型
Network
责任方
Principal Investigator
主要研究者

David Price

Professor David Price

Research in Real-Life Ltd

相似试验